NCT06007937 2026-02-05
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT04332367 2026-01-07
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT06251973 2025-12-02
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04069273 2025-07-31
SEQUEL
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05894824 2025-07-11
T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Yonsei University
Phase 1/2 Recruiting
NCT04660760 2024-04-01
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Academic and Community Cancer Research United
Phase 2 Recruiting